The Economics of Obesity Medicine Is Reshaping Healthcare

It has always been easy to overlook the economics of obesity. Any grocery store aisle will reveal a pattern: inexpensive calories are piled high on shelves, attractively packaged, and simple to prepare. Fresh veggies, on the other hand, are a little more expensive, a little less convenient, and frequently sit quietly in the corner. Although it’s a minor detail, economists have been pointing to it for decades, arguing that incentives may play a bigger role in the current obesity crisis than willpower.

Obesity rates have increased at an unprecedented rate over the last 50 years. Approximately 13% of Americans were considered obese in the early 1960s. The percentage is now closer to one-third. Rich nations are no longer the only ones experiencing this trend. The World Health Organization estimates that approximately 2.5 billion adults worldwide are overweight, with 890 million of them being obese. There is a growing perception that something more profound than individual behavior is at play as the numbers continue to rise year after year.

Doctors and economists typically approach the problem in different ways. Price is often where the story starts for them. Compared to other goods, food has become significantly less expensive. The cheapest options are frequently processed foods, which are high in fat and sugar. That change wasn’t an accident. Subsidies for crops like corn and soy, industrial food processing, and agricultural technology advancements all subtly changed what people ate. As a result, there is a market where meals high in calories are both widely available and often less expensive than healthier options.

Another factor that is difficult to overlook is convenience. A few decades ago, cooking an entire meal required patience, time, and effort. Dinner can now be prepared in three minutes using a microwave. Ovens humming in millions of kitchens is a simple technological change that may have had a greater impact on eating habits than any public health campaign ever could.

Concurrently, the economy has subtly decreased the demand for burning those calories. Factory floors have been replaced by office towers. Automation has replaced human labor in warehouses. The heavy lifting in even blue-collar jobs that formerly required physical strength is increasingly being done by machines. Despite producing more than ever before, workers’ bodies frequently move less. It’s difficult to miss the irony. Waistlines rise in tandem with productivity.

In light of this, medicine has made a new appearance in the narrative. For many years, diet plans, gym memberships, and counseling were the mainstays of obesity treatment. However, sustained success was difficult to achieve. Eventually, pharmaceutical companies filled the void by creating medications that control metabolism and hunger.

Now, businesses like Eli Lilly and Company and Novo Nordisk are at the vanguard of what appears to be a global medical race. Based on GLP-1 hormone pathways, their new class of weight-loss medications can have significant effects. Over the course of a year and a half, patients in certain trials lost more than twenty percent of their body weight.

The speed at which the financial markets responded is difficult to ignore. Investors reacted almost immediately when clinical data indicated that one experimental treatment might result in marginally better weight-loss outcomes than another. Shares changed dramatically. In one afternoon, market value of billions of dollars changed hands. Observing the response, it appears that Wall Street now sees obesity as a significant economic opportunity in addition to a health concern.

The figures contribute to the explanation. An estimated $147 billion is spent annually on obesity-related illnesses in the United States alone. The economic burden already accounts for more than 2% of the global GDP. According to some estimates, if current trends continue, the percentage may get close to 3.3 percent by 2060.

The discussion is altered by that scale. Suddenly, employers, insurance companies, governments, and pharmaceutical companies are all motivated to lower obesity rates or at the very least better manage the health effects.

However, there are still unanswered questions about the new obesity-drug economy. Without insurance, these drugs can cost hundreds of dollars a month. Such treatments are still very expensive for many patients, particularly in lower-income nations where obesity rates are increasing at the fastest rate.

Additionally, an odd paradox is developing. The urgency of preventing weight gain may wane as medicine improves in treating the effects of obesity, such as lowering cholesterol, managing diabetes, and controlling blood pressure. This is sometimes referred to by economists as moral hazard. People may feel less pressure to avoid a problem altogether if its costs seem reasonable.

It’s still unclear if that dynamic will influence obesity medicine in the future. It is evident that healthcare is changing. The distinction between a profitable pharmaceutical market and a public health emergency has become increasingly hazy.

It’s hard not to feel both optimistic and uneasy as you watch this unfold from a distance. The science is amazing. The medications are more effective than anything that physicians have previously used. However, the fundamental factors—cheap food, sedentary labor, and strong financial incentives—remain steadfast.

To put it another way, obesity treatment may be improving globally. The more difficult question is whether it is becoming more effective at stopping it. And as of right now, that response still seems ambiguous.